LIfT BioSciences granted €12M from Ireland’s Disruptive Technologies Innovation Fund to support the first-in-human clinical trial of LIfT’s IMAN therapy
Alex Blyth, Chief Executive Officer of LIfT Biosciences, said: “The grant awarded from DTIF is a significant milestone for LIfT as we expand our presence in Ireland and advance toward closing the second round of our Series A financing. By combining LIfT’s innovative immunotherapy platform with the University of Galway’s deep expertise in oncology, patient care, and advanced manufacturing, and Hooke Bio’s analytical expertise, we are enhancing our clinical-stage research and accelerating the path to delivering IMANs to patients. The majority of this grant will support CMC manufacturing and the clinical trial itself, positioning LIfT at the forefront of next-generation cancer immunotherapies.”
Share:
More News
“Pancreatic cancer has historically been one of the most difficult-to-treat cancers and people whose tumors harbor a KRAS G12C mutation face limited options once their disease progresses,” said Jacob Van Naarden, executive vice president, and president of Lilly Oncology. “This Breakthrough Therapy designation reflects the early potential we’re seeing with
“This financing reflects the confidence our investors and strategic partners have in the progress we have made to date and the opportunities that lie ahead,” said Dr. Jack Hoppin, Chief Executive Officer of Ratio Therapeutics. “As we march the ATLAS trial forward and prepare for our 5th IND filing, these
“We are excited to initiate monotherapy expansion evaluating IDE892 in MTAP-deleted PDAC and NSCLC. We designed IDE892 to be a potential best-in-class PRMT5 inhibitor, including approximately 1,400-fold selective MTA-PRMT5 cooperative binding versus SAM-PRMT5 cooperative binding, lack of brain penetrance, and favorable drug-like properties intended to maximize its therapeutic window as
“The data presented at ASCO provided important insight into the potential clinical path for CRB-701 in 2L oropharyngeal cancer, a distinct tumor-type that is on the rise due to HPV infections,” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. “Unfortunately, current treatment options have shown limited efficacy underscoring the